Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Zepbound (tirzepatide) can cause side effects that range from mild to serious. More common side effects include nausea, diarrhea, and constipation. If side effects from Zepbound become hard to ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

In addition, the results showed that it has the potential to compete with Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). Amgen expects its revenue to be between $34.3 billion ...

Amgen’s stock has been rising consistently ... s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy, which are weekly injections.